On November 20, 2024, CytoMed Therapeutics announced that the first patient has been dosed in its ANGELICA Trial, a Phase I clinical trial for its CAR-gamma delta T cell therapy targeting advanced solid tumors and hematological malignancies.
AI Assistant
CYTOMED THERAPEUTICS LTD
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.